Founded as the first manufacturer of the market in its category in 2002 by Prof. Dr. Haluk Ataoğlu, Matriks Biotek® produces ELISA test kits and monoclonal antibodies for research and better understanding of the diseases. The Matriks Biotek® “Shikari®” ELISA kits and anti-drug antibody ELISA kits can be efficiently used, for monitoring serum trough levels and the presence of anti-drug antibodies respectively, during therapy and offers the scientist a tool for taking decisions on possible preventive measures.
There is a continuous R&D on going on at the company. Major fields are inflammation, infectious diseases, Obesity, type II diabetes and cardiovascular diseases, where we try to understand the pathophysiology, develop targets for diagnosis and treatment.
Our products are exported to 35 countries mainly to North America, Europe, Israel, India, Japan, China and Australia. We have 20 distributors all over the world.
Contact
Gazi Üniversitesi Gölbaşı Yerleşkesi Teknoplaza Binası (B Blok Zemin Kat BZ17) 06830
Gölbaşı, ANKARA, TÜRKİYE
Phone: +90 (312) 485 42 94
Fax: +90 (312) 485 11 87
E-Mail: info@matriksbiotek.com
Haluk Ataoglu, academic turned founder of Matriks Biotek®, talks about his aspirations for his company and the Turkish R&D landscape as well as how to penetrate the global pharmaceutical market…
A roundup of the biggest pharma and healthcare stories from Turkey including the investigation of 19 pharma companies by the country’s competition watchdog; Gen Pharma Caucasus Manufacturing’s new plant in…
A roundup of the latest pharma and healthcare news from Turkey including Omya’s new Turkish manufacturing site, Santa Farma’s fourth EU-GMP certification and the collaboration agreement between BioNTech and Turkey’s…
A roundup of the latest pharma and healthcare news from Turkey including Roche Turkey’s digital platform for HCPs and patients, big pharma’s aid to earthquake victims, the Scientific and Technological…
The Middle East and Africa (MEA), the fifth-largest regional pharma market in the world, is rapidly becoming a pharmaceutical powerhouse with both global and local firms taking advantage of the…
After its best financial year to date – posting revenues of USD 27.3 billion in 2021 – Gilead has said yes to localization in Turkey. The California-based company, known for…
Turkey’s pharma market, the 18th largest in the world and valued at USD 7 Billion in 2020, has seen steady growth over the past few years due to favorable healthcare…
With an already well-established manufacturing industry for pharmaceuticals, Turkey has been aiming to move with global trends and invest in biologics production, specifically in biosimilars. The share of biotechnological…
Becoming the clinical trials country leader in the region has been set as a primary goal for Turkey’s pharma industry to achieve global competitiveness. The government’s strategy is to increase…
Few Turkish companies are experiencing such a transformational moment as GEN. In 2021 alone, the Ankara-based organization made its public debut on the Istanbul Stock Exchange and signed an exclusive…
When the Turkish Ministry of Health implemented its strategy to transition from import pharmaceuticals to manufacturing them at home in 2016, the local industry leveraged the situation to invest in…
As an upper-middle-income country with an emerging economy, Turkey could not invest billions in COVID-19 vaccine R&D, but a strong research ecosystem and willing industry allowed it to kickstart multiple…
Overseeing healthcare for a population of over 80 million, Turkey’s Ministry of Health was put under the spotlight during the COVID-19 pandemic. Here, we highlight four of the hot-button items…
See our Cookie Privacy Policy Here
